SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003; 53: 208226.
  • 2
    RiesLAG, EisnerMP, KosaryCL, et al. (eds). SEER Cancer Statistics Review, 1975–2000. Bethesda, MD: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2000. Accessed August 29, 2003
  • 3
    Yancik R, Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000; 14: 1723.
  • 4
    Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003; 95: 4708.
  • 5
    Woloshin S, Schwartz LM, Welch HG. Risk charts: putting cancer in context. J Natl Cancer Inst 2002; 94: 799804.
  • 6
    Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999; 86: 186776.
  • 7
    Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 20617.
  • 8
    Stafford RS, Cyr PL. The impact of cancer on the physical function of the elderly and their utilization of health care. Cancer 1997; 80: 197380.
  • 9
    Narain P, Rubenstein LZ, Wieland GD, et al. Predictors of immediate and 6-month outcomes in hospitalized elderly patients. The importance of functional status. J Am Geriatr Soc 1988; 36: 77583.
  • 10
    Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000; 5: 22437.
  • 11
    Reuben DB, Rubenstein LV, Hirsch SH, Hays RD. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med 1992; 93: 6639.
  • 12
    Barberger-Gateau P, Fabrigoule C, Helmer C, et al. Functional impairment in instrumental activities of daily living: an early clinical sign of dementia? J Am Geriatr Soc 1999; 47: 45662.
  • 13
    Landi F, Zuccala G, Gambassi G, et al. Body mass index and mortality among older people living in the community. J Am Geriatr Soc 1999; 47: 10726.
  • 14
    Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69: 4917.
  • 15
    Newman AB, Yanez D, Harris T, et al. Weight change in old age and its association with mortality. J Am Geriatr Soc 2001; 49: 130918.
  • 16
    Eagles JM, Beattie JA, Restall DB, et al. Relation between cognitive impairment and early death in the elderly. BMJ 1990; 300: 23940.
  • 17
    Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344: 11116.
  • 18
    Seeman TE, Berkman LF, Kohout F, et al. Intercommunity variations in the association between social ties and mortality in the elderly. A comparative analysis of three communities. Ann Epidemiol 1993; 3: 32535.
  • 19
    Vestal RE. Aging and pharmacology. Cancer 1997; 80: 130210.
  • 20
    Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 161826.
  • 21
    Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986; 4: 7029.
  • 22
    Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 2532.
  • 23
    Borges M, Sculier JP, Paesmans M, et al. Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC). Lung Cancer 1996; 16: 2133.
  • 24
    Hillner BE, McDonald MK, Desch CE, et al. A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort. Cancer 1998; 83: 19307.
  • 25
    Smith TJ, Penberthy L, Desch CE, et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 1995; 13: 23552.
  • 26
    Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 17107.
  • 27
    National Center for Health Statistics. United States Life Tables, 2000. Available at http://www.cdc.gov/nchs/products/pubs/pubd/nvsr/51/51_03.htm. Accessed August 29, 2003
  • 28
    Hanagiri T, Muranaka H, Hashimoto M, et al. Results of surgical treatment of lung cancer in octogenarians. Lung Cancer 1999; 23: 12933.
  • 29
    Pagni S, Federico JA, Ponn RB. Pulmonary resection for lung cancer in octogenarians. Ann Thorac Surg 1997; 63: 7859.
  • 30
    Yamamoto K, Padilla Alarcon J, Calvo Medina V, et al. Surgical results of stage I non-small cell lung cancer: comparison between elderly and younger patients. Eur J Cardiothorac Surg 2003; 23: 215.
  • 31
    Jazieh AR, Hussain M, Howington JA, et al. Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. Ann Thorac Surg 2000; 70: 116871.
  • 32
    van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 2000; 117: 3749.
  • 33
    Cohen H. Cancer care in the older population: physiology of aging. Presented at the American Society of Clinical Oncology Educational Symposium; November 5–6, 2000; Orlando, Fla.
  • 34
    Janssen-Heijnen ML, Schipper RM, Razenberg PP, et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998; 21: 10513.
  • 35
    Dyszkiewicz W, Pawlak K, Gasiorowski L. Early post-pneumonectomy complications in the elderly. Eur J Cardiothorac Surg 2000; 17: 24650.
  • 36
    Bach PB, Cramer LD, Schrag D, et al. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001; 345: 1818.
  • 37
    Gauden SJ, Tripcony L. The curative treatment by radiation therapy alone of Stage I non-small cell lung cancer in a geriatric population. Lung Cancer 2001; 32: 719.
  • 38
    Pignon T, Gregor A, Schaake Koning C, et al. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol 1998; 46: 23948.
  • 39
    Numico G, Russi E, Merlano M. Best supportive care in non-small cell lung cancer: Is there a role for radiotherapy and chemotherapy? Lung Cancer 2001; 32: 21326.
  • 40
    Langer CJ, Hsu C, Curran W, et al. Do elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC) benefit from combined modality therapy? A secondary analysis of RTOG 94–10. I. J. Radiat Oncol Biol Physics 2002; 51(Suppl 1): 201.
  • 41
    Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117: 35864.
  • 42
    Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999; 45: 11439.
  • 43
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899909.
  • 44
    Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 2001; 19: 106470.
  • 45
    Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91: 6672.
  • 46
    Ricci S, Antonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. Lung Cancer 2000; 27: 7580.
  • 47
    McKay CE, Hainsworth JD, Burris HA 3rd, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a Minnie Pearl Cancer Network Phase II Trial. Proc Am Soc Clin Oncol 2000; 19: 502a. Abstract 1964.
  • 48
    Fidias P, Supko JG, Martins R, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001; 7: 39429.
  • 49
    Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 36272.
  • 50
    Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18: 252936.
  • 51
    Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 17381.
  • 52
    Kelly K, Giarritta S, Akerley W, et al. Should older patients (Pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 2001; 20: 329a. Abstract 1313.
  • 53
    Hensing TA, Socinski MA, Schell MJ, et al. Age does not alter toxicity or survival for patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) treated with carboplatin (C) and paclitaxel (P). Proc Am Soc Clin Oncol 2001; 20: 346a. Abstract 1382.
  • 54
    Lilenbaum RC, Herndon J, List M, et al. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol 2002; 21: 1a. Abstract 2.
  • 55
    Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 (‘Iressa’) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21: 292a. Abstract 1166.
  • 56
    Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003; 21: 223746.
  • 57
    Gridelli C, De Vivo R, Monfardini S. Management of small cell lung cancer in the elderly. Crit Rev Oncol Hematol 2002; 41: 7988.
  • 58
    Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 2002; 346: 8591.
  • 59
    Shepherd FA, Amdemichael E, Evans WK, et al. Treatment of small cell lung cancer in the elderly. J Am Geriatr Soc 1994; 42: 6470.
  • 60
    Siu LL, Shepherd FA, Murray N, Feld R, et al. Influence of age on the treatment of limited-stage small cell lung cancer. J Clin Oncol 1996; 14: 8218.
  • 61
    Larive S, Bombaron P, Riou R, et al. Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial. Lung Cancer 2002; 35: 17.
  • 62
    Matsui K, Masuda N, Fukuoka M, et al. Phase II trial of carboplatin plus oral etoposide for elderly patients with small cell lung cancer. Br J Cancer 1998; 77: 19615.
  • 63
    Okamoto H, Watanabe K, Nishiwaki Y, et al. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small cell lung cancer. J Clin Oncol 1999; 17: 35403545.
  • 64
    Carney DN. Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer. Lung Cancer 1995; 12(Suppl 3): S77S83.
  • 65
    Evans WK, Radwi A, Tomiak E, et al. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 1995; 18: 149155.
  • 66
    Smit EF, Carney DN, Harford P, et al. A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 1989; 44: 631633.
  • 67
    Carney DN, Grogan L, Smit EF, et al. Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 1990; 17: 4953.
  • 68
    Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996; 348: 5636.
  • 69
    Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89: 57780.
  • 70
    Murray N, Grafton C, Shah A, et al. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small cell lung cancer. J Clin Oncol 1998; 16: 33238.
  • 71
    Westeel V, Murray N, Gelmon K, et al. New combination of the old drugs for elderly patients with small cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol 1998; 16: 19407.
  • 72
    Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327: 161824.
  • 73
    Quon H, Shepherd FA, Payne DG, et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 1999; 43: 3945.
  • 74
    Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a phase II study. Cancer 1998; 82: 83641.
  • 75
    Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000; 89: 195360.
  • 76
    Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341: 47684.
  • 77
    Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994; 12: 62742.